Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion's distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.

More information Original publication

DOI

10.1192/bjp.2025.50

Type

Journal article

Publication Date

2025-12-01T00:00:00+00:00

Volume

227

Pages

833 - 835

Total pages

2

Keywords

Bupropion, depression, inflammation, licensing, sexual dysfunction, Humans, Bupropion, United Kingdom, Depressive Disorder, Treatment-Resistant, Antidepressive Agents, Second-Generation, Selective Serotonin Reuptake Inhibitors, Drug Repositioning, Sexual Dysfunction, Physiological